MATEON IS SELECTED BY IBM WATSON HEALTH FOR THE USE OF IBM CLINICAL DEVELOPMENT SOLUTION AT NO COST FOR PHASE II CLINICAL TRIAL OF OT-101 FOR COVID-19
June 24, 2020 07:00 ET
|
Mateon Therapeutics, Inc.
Mateon was approved to use the platform following a review of the program as part of IBM Watson Health’s effort to help support and accelerate promising clinical COVID-19 candidates AGOURA HILLS,...